GSK is set to acquire the exclusive rights for Syndivia’s preclinical antibody-drug conjugate (ADC), which is currently in ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

GSK (GSK) announced an agreement granting GSK exclusive worldwide rights to develop and commercialise a preclinical ADC for mCRPC. The novel ADC, ...

London: GSK plc and Syndivia, a private biotechnology company focused on next-generation ADCs, have announced an agreement ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

GSK stock has seen a modest increase in its Fair Value Estimate, climbing from $16.51 to $16.63 per share while the discount ...

Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...

This model, combining technology, trusted partners, and personalized engagement, offers a blueprint for a prevention-first ...

EMA committee issues positive opinion to support the approval of GSK’s recombinant zoster vaccine, Shingrix in a prefilled syringe: London, UK Wednesday, October 22, 2025, 16:00 ...

Settlement reached over mRNA-based COVID vaccines CureVac and GSK get $740 million upfront, and royalties BioNTech's deal to buy CureVac on track GSK's own lawsuits against Pfizer, BioNTech unaffected ...

CNW/ - Dalhousie University, in collaboration with Nova Scotia Health's INSPIRED COPD Outreach Program, the Nova Scotia ...